Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program

被引：0

作者：

Park, Soo Jin ^{[1
]}

Lee, Yoo Young ^{[2
]}

Kim, Kidong ^{[3
]}

Nam, Eun Ji ^{[4
]}

Lim, Myong Cheol ^{[5
]}

Kim, Min Kyu ^{[6
]}

Kim, Ki Hyung ^{[7
]}

Kwon, Yong-Soon ^{[8
]}

机构：

[1] Seoul Natl Univ Hosp, Obstet & Gynecol, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Gynecol Canc Ctr, Dept Obstet & Gynecol,Sch Med, Seoul, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, Seongnam Si, South Korea

[4] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Div Gynecol Oncol,Coll Med, Seoul, South Korea

[5] Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea

[6] Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Obstet & Gynecol, Chang Won, South Korea

[7] Pusan Natl Univ Hosp, Obstet & Gynecol, Busan, South Korea

[8] Eulji Univ, Coll Med, Nowon Eulji Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.230

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP134

引用

页码：A131 / A132

页数：2

共 50 条

[31] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Oaknin, Ana
Gilbert, Lucy
Tinker, Anna, V
Brown, Jubilee
Mathews, Cara
Press, Joshua
Sabatier, Renaud
O'Malley, David M.
Samouelian, Vanessa
Boni, Valentina
Duska, Linda
Ghamande, Sharad
Ghatage, Prafull
Kristeleit, Rebecca
Leath, Charles, III
Guo, Wei
Im, Ellie
Zildjian, Sybil
Han, Xinwei
Duan, Tao
Veneris, Jennifer
Pothuri, Bhavana
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
[32] Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer
Kothari, Anai
White, Michael G.
Peacock, Oliver
Kaur, Harmeet
Palmquist, Sarah M.
You, Nancy
Taggart, Melissa
Salem, Usama
Overman, Michael
Kopetz, Scott
Chang, George J.
BRITISH JOURNAL OF SURGERY, 2022, 109 (06) : 489 - 492
[33] PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
Liu, Ding-Xin
Li, Dan-Dan
He, Wan
Ke, Chuan-Feng
Jiang, Wu
Tang, Jing-Hua
Kong, Ling-Heng
Li, Yuan
Sui, Qiao-Qi
Xiao, Bin-Yi
Li, Wei-Rong
Hong, Zhi-Gang
Xu, Rui-Hua
Pan, Zhi-Zhong
Zhang, Xiao-Shi
Ding, Pei-Rong
ONCOIMMUNOLOGY, 2020, 9 (01):
[34] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
Bekaii-Saab, Tanios S.
ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
[35] Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Colle, Raphael
Radzik, Anna
Cohen, Romain
Pellat, Anna
Lopez-Tabada, Daniel
Cachanado, Marine
Duval, Alex
Svrcek, Magali
Menu, Yves
Andre, Thierry
EUROPEAN JOURNAL OF CANCER, 2021, 144 : 9 - 16
[36] Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Chu, Jacqueline N.
Choi, Jin
Ostvar, Sassan
Torchia, James A.
Reynolds, Kerry Lynn
Tramontano, Angela
Gainor, Justin F.
Chung, Daniel C.
Clark, Jeffrey W.
Hur, Chin
CANCER, 2019, 125 (02) : 278 - 289
[37] Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Valabrega, Giorgio
Powell, Matthew A.
Hietanen, Sakari
Miller, Eirwen M.
Novak, Zoltan
Holloway, Robert
Denschlag, Dominik
Myers, Tashanna
Thijs, Anna M.
Pennington, Kathryn P.
Gilbert, Lucy
Fleming, Evelyn
Zub, Oleksandr
Landrum, Lisa M.
Ataseven, Beyhan
Gogoi, Radhika
Podzielinski, Iwona
Cloven, Noelle
Monk, Bradley J.
Sharma, Sudarshan
Herzog, Thomas J.
Stuckey, Ashley
Pothuri, Bhavana
Secord, Angeles Alvarez
Chase, Dana
Vincent, Veena
Meyers, Oren
Garside, Jamie
Mirza, Mansoor Raza
Black, Destin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
[38] Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study
O'Malley, D. M.
Bariani, G. M.
Cassier, P. A.
Marabelle, A.
Hansen, A. R.
Acosta, A. De Jesus
Miller, W. H., Jr.
Safra, T.
Italiano, A.
Mileshkin, L.
Amonkar, M.
Jin, F.
Yao, L.
Norwood, K.
Maio, M.
GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 245 - 253
[39] Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies
Li, Ying-Jie
Liu, Xin-Zhi
Yao, Yun-Feng
Chen, Nan
Li, Zhong-Wu
Zhang, Xiao-Yan
Lin, Xin-Feng
Wu, Ai-Wen
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2023, 15 (02): : 222 - 233
[40] Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158
Xu, Jianming
Mao, Yimin
Xu, Nong
Bai, Yuxian
Wang, Dong
Chen, Xiaojun
Yin, Xianli
Deng, Yanhong
Yang, Jianwei
Zhang, Jieqing
Tang, Jie
Huang, Yi
Li, Jiayi
Luo, Suxia
Zheng, Hong
Zhao, Weidong
Xu, Miaomiao
Li, Nan
Mao, Yixiang
Gozman, Alexander
Wu, Xiaohua
IMMUNOTHERAPY, 2024, 16 (08) : 529 - 537

← 1 2 3 4 5 →